Our results suggest that BAX status may not alter clinical response to HSP90 inhibitors and indicate that additional drugs may be required in combination to increase tumor-selective cell killing by these clinically promising drugs, such as combination with TRAIL [43] or HSP70 inhibitors [20]. This evidence concerns the gene TNFSF10 and neoplasm.